Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Turn to the experienced analysts and deep wells of data at Informa Pharma Intelligence for all your clinical trial data needs. Our teams of subject matter experts deliver essential clinical trial data analysis, using data drawn from the most robust clinical trial database available.
Scrip
By Alex Shimmings 18 Oct 2019
Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.
Scrip
By Brian Yang 18 Oct 2019
Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.
Topic Deal trends Strategy
Scrip
By Andrew McConaghie 18 Oct 2019
Investor's Downfall is Unwelcome Distraction: As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
Scrip
By Mandy Jackson 18 Oct 2019
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
Scrip
By Andrew McConaghie 18 Oct 2019
Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting.
Topic Research BioPharmaceutical
Scrip
By Mandy Jackson 18 Oct 2019
One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.
Topic Cell and gene therapy
Biomedtracker, Meddevicetracker
16 Oct 2019
What major drug catalysts and events can you expect to see this quarter? Get a view of what's to come with an extract from the full report.
Meddevicetracker
16 Oct 2019
What were the outcomes of critical catalysts featured in Meddevicetracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.
Topic Drug approval
Biomedtracker
16 Oct 2019
What were the outcomes of critical catalysts featured in Biomedtracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.
Topic Drug approval Drug review FDA
Pink Sheet
16 Oct 2019
When you look at newly approved drugs, the latest product reviews and the decisions made during the process, you can gain critical insights to inform your own strategic decisions. That’s what Pink Sheet delivers, and now you can try it for free.
Pink Sheet
16 Oct 2019
Keep track of compliance, legislation, policy regulations, and industry developments with the expertise of our worldwide network of expert analysts and journalists on the ground in key global regions.
Scrip
14 Oct 2019
Find out how the consequences of the opioids crisis is affecting the pharma industry, from shaping the way deals are made, to transforming the development of new categories of drugs. Scrip brings you the implications behind the headlines in an essential free article pack.
Pink Sheet
14 Oct 2019
With the opioid crisis in full swing in the US, government and regulatory agencies are announcing changes to guidance and legislation related to both new and existing drugs. Keep abreast of these critical changes with essential coverage from Pink Sheet.
Topic Drug approval FDA
Trialtrove
11 Oct 2019
A clear view of the past is often the surest way to plan for the future. The annual analysis of Phase I-III clinical trials from Citeline’s Trialtrove reveals the priorities and strategies of the biopharma industry. This infographic lets you clearly see the players, trials, and trends.
Topic Drug development landscape BioPharmaceutical Business strategies
Trialtrove
11 Oct 2019
See last year’s clinical trial activity through the eyes of our expert analysts and get a better sense of where the industry is headed. This new whitepaper is the annual analysis of Phase I-III clinical trials, from Citeline’s Trialtrove, and reveals the priorities and strategies of the biopharma industry.
Topic Drug development landscape BioPharmaceutical Business strategies
Pink Sheet
18 Oct 2019
Scrip
18 Oct 2019
Medtech Insight
18 Oct 2019
Pink Sheet
18 Oct 2019
Scrip
18 Oct 2019
Scrip
18 Oct 2019
Medtech Insight
18 Oct 2019
Scrip
18 Oct 2019
Pink Sheet
18 Oct 2019
Scrip
18 Oct 2019
Medtech Insight
18 Oct 2019
Pink Sheet
18 Oct 2019
Medtech Insight
18 Oct 2019
Medtech Insight
18 Oct 2019
Medtech Insight
18 Oct 2019
Approximately 400,000 investigators in over 170 countries, all with clinical trial experience, all at your fingertips. Support your trial success and inform your principal investigator (PI) and site selection activities with Sitetrove, now on a sleek, modern interface for simpler, faster and more efficient searching.
Key benefits:
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Key benefits:
The industry’s most trusted drug development database, Citeline's Pharmaprojects has been covering pharma R&D across global markets for 35+ years. With 68,000+ drug profiles including 15,000 drugs in active development, it’s the go-to resource for preclinical, clinical, and pipeline coverage, and lifecycle management tracking.
Key benefits:
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
